PHARMA LITERATI

Narasimhan succeeds Joseph Jimenez who will step down in 2018 after eight years in the position Global pharma major Novartis on Monday named Vasant Narasimhan as its new Chief Executive Officer from February 1, 2018. He succeeds Joseph Jimenez who will step down in 2018 after eight years in the position, Novartis said in a statement. Narasimhan is currently Global Head of Drug Development and Chief Medical Officer of the company and is also member of the Executive Committee of the company, it added. Commenting on the development, Novartis Board of Directors Chairman Joerg Reinhardt said: " We anticipate a smooth transition as Joe built a strong leadership team and mentored his successor. Novartis will be well positioned to continue its momentum ." Both from a professional and a personal perspective, this is the right moment to hand the leadership reins of the company to Vas, Jimenez said. Narasimhan has held numerous leadership positions across Novartis ...

Drug Name Luseogliflozin Structure   Drug Code TS-071 Synonym (2S,3R,4R,5S,6R)-2-[5-(4-Ethoxybenzyl)-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol Molecular Formula C 23 H 30 O 6 S Innovator Taisho Toyama Pharmaceutical Novartis for marketing Condition Type-2 diabetes mellitus Mechanism of Action Sodium-glucose transporter 2 inhibitor Clinical Phase I Approval Approved in Japan in March 2014.

Drug Name (S)-Pyrrolidine-2-carboxylic acid compound with (2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1) Structure   Drug Code LIK-066 Synonym - Molecular Formula C 23 H 28 O 7 .2 C 6 H 11 NO Innovator Novartis Condition Type-2 diabetes mellitus Mechanism of Action Sodium-glucose transporter 2 inhibitor Clinical Phase II in USA